Orforglipron

Orforglipron is a once-daily, oral, non-peptide small-molecule GLP-1 receptor agonist — and as of 1 April 2026 it is FDA-approved, marketed by Eli Lilly as Foundayo™ for chronic weight management. Discovered by Chugai Pharmaceutical and licensed by Eli Lilly in 2018, it activates the GLP-1 receptor through the transmembrane domain (a non-canonical site) with Gs/cAMP-biased signaling. As a small molecule it can be taken as a pill at any time of day without food or water restrictions — answering the needle and cold-chain barriers of peptide GLP-1s.

Source: FOUNDAYO (orforglipron calcium) — NDA 220934, FDA approval 1 April 2026, FDA / Eli Lilly, via Drugs@FDA + FDA press announcement

What is Orforglipron and why does an oral small-molecule GLP-1 matter?

Orforglipron delivers GLP-1-receptor activation in a pill rather than an injection, which materially widens access to incretin therapy. It is not a peptide (unlike semaglutide); it belongs to the oral small-molecule GLP-1 class, and its verification chemistry is small-molecule (HPLC + MS), not peptide sequencing. A precision point worth making: it is the first non-peptide oral GLP-1 approved for obesity, but not the first oral GLP-1 outright — oral semaglutide (a peptide formulation) was approved for obesity in December 2025. Unlike that product, Foundayo carries no food or water timing restrictions.

Source: Novo Nordisk announcement — FDA approval of Wegovy® pill (oral semaglutide 25 mg) for weight management, Novo Nordisk, via novonordisk.com (company announcement)

What does the clinical evidence show?

Orforglipron completed a large Phase 3 program — ACHIEVE (type 2 diabetes) and ATTAIN (obesity) — with the ATTAIN-1 obesity trial (published in NEJM) showing roughly 11–12% weight loss at 72 weeks and A1C reductions consistent with injectable GLP-1s. That package supported the FDA approval, granted 50 days after filing under the Commissioner's National Priority Voucher pilot — the fastest new-molecular-entity approval since 2002.

Sources: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment, Wharton S. et al., N Engl J Med, 2025; FOUNDAYO (orforglipron calcium) — NDA 220934, FDA approval 1 April 2026, FDA / Eli Lilly, via Drugs@FDA + FDA press announcement · Evidence level: phase 3 (multiple RCTs); FDA-approved April 2026

What are the documented side effects of Orforglipron?

The label carries a boxed warning for thyroid C-cell tumours, including medullary thyroid carcinoma — it is contraindicated in anyone with a personal or family history of MTC or multiple endocrine neoplasia type 2 — and the common adverse effects are predominantly gastrointestinal (nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain), plus headache, fatigue and hair loss. Notably, unlike the discontinued oral small-molecule danuglipron, orforglipron did not show the hepatotoxicity that halted that competitor.

Evidence level: phase 3 + approved label

What is the regulatory status, and what does that mean for research-market material?

Orforglipron is an FDA-approved prescription medicine (Foundayo, approved 1 April 2026 under NDA 220934) dispensed through pharmacies and Lilly's direct channel — which means any "orforglipron" sold by a research-chemical vendor is not the approved product, has not been through that manufacturing and quality chain, and cannot be assumed to contain what the label claims. That closed distribution chain is the red flag to understand: no legitimate supply route delivers Foundayo to research-chemical vendors, so gray-market "orforglipron" is by definition not the pharmacy product. It also is not a peptide — a vendor listing "orforglipron" alongside peptide vials, or supplying a COA built on peptide-style HPLC purity alone, is advertising the wrong verification for a small-molecule drug; identity requires small-molecule LC-MS confirmation. Counterfeit and substitute risk is therefore higher here than for compounds with an established research-chemical history. For an approved drug, the gap between the pharmacy product and grey-market powder is the whole story. See the legal status guide.

Source: FOUNDAYO (orforglipron calcium) — NDA 220934, FDA approval 1 April 2026, FDA / Eli Lilly, via Drugs@FDA + FDA press announcement

Why does vendor verification matter, and how does Peptigrity verify?

Because an approved-drug name on a research vial is a marketing claim, not a guarantee — HPLC and mass-spec identity are the only objective checks that the material is even the right compound at the labelled amount. Peptigrity collects independent third-party Certificates of Analysis from shops' official channels and verifies each for authenticity before publishing — because shops choose which COAs to publish, results reflect the batches made public rather than every production batch, a selection bias we state openly. A community-funded Testing Grant to purchase and test vials anonymously is in development. The trust score weights lab purity and reviews equally (50/50). See how to read lab results.

Educational information only; not medical advice. Orforglipron is an FDA-approved prescription medicine (Foundayo, approved 1 April 2026) and carries a boxed warning for thyroid C-cell tumours; research-market material is not the approved product. Consult a qualified healthcare provider. Peptigrity does not sell, endorse, or recommend products or vendors.

Frequently asked questions